ARCA biopharma, Inc. Form 4

September 19, 2014

OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION **OMB** 3235-0287 Washington, D.C. 20549 Number: Check this box January 31, Expires: if no longer 2005 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to Estimated average **SECURITIES** Section 16. burden hours per Form 4 or response... 0.5 Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading **BRISTOW MICHAEL R** Issuer Symbol ARCA biopharma, Inc. [ABIO] (Check all applicable) (First) (Middle) 3. Date of Earliest Transaction (Last) (Month/Day/Year) _X__ Director 10% Owner Other (specify X_ Officer (give title ARCA BIOPHARMA, INC., 11080 09/18/2014 below) CIRCLEPOINT ROAD, SUITE 140 President and CEO (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting WESTMINSTER, CO 80020 (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of	2. Transaction Date	2A. Deemed	3.	4. Securities Acquired			5. Amount of	6.	7. Nature of
Security	(Month/Day/Year)	Execution Date, if	Transactio	ction(A) or Disposed of			Securities	Ownership	Indirect
(Instr. 3)		any	Code	(D)			Beneficially	Form: Direct	Beneficial
		(Month/Day/Year)	(Instr. 8)	(Instr. 3, 4	and 5	5)	Owned	(D) or	Ownership
							Following	Indirect (I)	(Instr. 4)
					(4)		Reported	(Instr. 4)	
					(A)		Transaction(s)		
			C 1 W		or	ъ.	(Instr. 3 and 4)		
~			Code V	Amount	(D)	Price			
Common	09/18/2014		S	13,853	D	\$	292,625 (2)	D	
Stock	07/10/2014		S	<u>(1)</u>		1.3	272,023	Ъ	
									D
									By
Common							139,082	I	Investocor
Stock							139,062	1	Trust as
									sole Trustee
									By NFS
_									Custodian
Common							178,215	I	for Michael
Stock							170,213	1	
									Bristow's
									IRA

Edgar Filing: ARCA biopharma, Inc. - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exerc	cisable and	7. Title	and	8. Price of	
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transac	tionNumber	Expiration D	ate	Amoun	t of	Derivative	į
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Underly	ying	Security	į
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8	Derivativ	e		Securiti	ies	(Instr. 5)	Ī
	Derivative				Securities	S		(Instr. 3	3 and 4)		
	Security				Acquired						1
					(A) or						1
					Disposed						,
					of (D)						
					(Instr. 3,						
					4, and 5)						
									\ mount		
						Date	Expiration				
						Exercisable	Exercisable Date				
				Code '	V (A) (D)						
	Derivative Security	Security or Exercise (Instr. 3) Price of Derivative	Derivative Conversion (Month/Day/Year) Security or Exercise (Instr. 3) Price of Derivative	Derivative Conversion (Month/Day/Year) Execution Date, if Security or Exercise any (Month/Day/Year) Price of (Month/Day/Year) Derivative	Derivative Conversion (Month/Day/Year) Execution Date, if Transaction or Exercise any Code (Instr. 3) Price of (Month/Day/Year) (Instr. 8) Derivative Security	Derivative Conversion or Exercise any Code of (Instr. 3) Price of Derivative Security Security One Exercise any Code of (Instr. 8) Derivative Security Security Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Derivative Conversion (Month/Day/Year) Execution Date, if TransactionNumber Expiration D any Code of (Month/Day/Year) Code of (Month/Day/Year) (Instr. 8) Derivative Security Security Security Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Derivative Conversion (Month/Day/Year) Execution Date, if any Code of (Month/Day/Year) (Instr. 3) Price of Derivative Security Security Security Security Security Date Security Security Security Date Expiration Date Securities Secu	Derivative Conversion (Month/Day/Year) Execution Date, if TransactionNumber Expiration Date Amount Security or Exercise any Code of (Month/Day/Year) Underly Code of (Month/Day/Year) Underly Securities Securities Securities (Instr. 3) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) Date Expiration Date Amount Code of (Month/Day/Year) Underly Securities (Instr. 3) Date Expiration Exercisable Date Title Instr. 3	Derivative Conversion or Exercise (Instr. 3) Price of Derivative Security Security Derivative Security TransactionNumber Code of (Month/Day/Year) Price of Derivative Security Security Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) Date Expiration Date (Month/Day/Year) Amount of Underlying Securities (Instr. 3 and 4) Amount of (Month/Day/Year) Underlying Securities (Instr. 3 and 4) Amount of (Month/Day/Year) Underlying Securities (Instr. 3 and 4) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) Amount or Title Number of	Derivative Conversion (Month/Day/Year) Execution Date, if TransactionNumber of Expiration Date any Code of (Month/Day/Year) Underlying Security (Instr. 3) Price of Derivative Security Securities (Instr. 5) Derivative Security Securities (Instr. 5) Derivative Security Securities (Instr. 5) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) Underlying Security (Instr. 5) Instr. 3 and 4) Amount of Derivative Securities (Instr. 5) Derivative Securities (Instr. 3, 4, and 5)

Reporting Owners

	Relationships
Renorting Owner Name / Address	•

Director 10% Owner Officer Other

BRISTOW MICHAEL R ARCA BIOPHARMA, INC. 11080 CIRCLEPOINT ROAD, SUITE 140 WESTMINSTER, CO 80020

X

President and CEO

Signatures

/s/ Patrick M. Wheeler,
Attorney-in-Fact

09/19/2014

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person for satisfaction of their tax withholding obligation with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Equity Incentive Plan (the "Plan").
- Includes (i) remaining 83,334 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments on 9/17/15 and 9/17/16, and (ii) 56,700 previously reported shares issued as RSUs under the Plan that vest in four equal annual installments beginning on 2/27/15, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Reporting Owners 2

Edgar Filing: ARCA biopharma, Inc. - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.